{"id":927662,"date":"2026-04-30T02:55:19","date_gmt":"2026-04-30T02:55:19","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/927662\/"},"modified":"2026-04-30T02:55:19","modified_gmt":"2026-04-30T02:55:19","slug":"a-look-at-bristol-myers-squibb-bmy-valuation-after-upbeat-2026-guidance-and-cost-cutting-progress","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/927662\/","title":{"rendered":"A Look At Bristol Myers Squibb (BMY) Valuation After Upbeat 2026 Guidance And Cost-Cutting Progress"},"content":{"rendered":"\n

Never miss an important update on your stock portfolio<\/a> and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.<\/p>\n

Bristol-Myers Squibb (BMY) has drawn fresh attention after issuing 2026 revenue and adjusted EPS guidance that exceeded Wall Street expectations, lifting the stock as investors focused on Opdivo, Eliquis, and ongoing cost-cutting efforts.<\/p>\n

See our latest analysis for Bristol-Myers Squibb.<\/a><\/p>\n

While the latest guidance moved the stock higher on the day, the 90 day share price return of 6.10% and year to date share price return of 7.73% suggest momentum has been building. The 1 year total shareholder return of 20.45% sits against a more muted 3 year total shareholder return of 0.71% and 5 year total shareholder return of 8.85%, showing how recent optimism contrasts with a more moderate longer term record.<\/p>\n

If this kind of renewed interest in big pharma has your attention, it could be a good moment to look at 32 healthcare AI stocks<\/a> as another way to find healthcare names with a different growth profile.<\/p>\n

With Bristol-Myers Squibb trading at a discount to analyst targets and an estimated intrinsic value gap of more than 50%, the key question is whether this reflects genuine undervaluation or whether the market already captures future growth potential.<\/p>\n

Most Popular Narrative: 11.4% Undervalued <\/p>\n

The narrative fair value of $65.00 sits above Bristol-Myers Squibb’s last close at $57.59, which puts the current rally in a different light according to Evangelos.<\/p>\n

\n

Full-Year 2024 Highlights:<\/p>\n

Total Revenues: $48.3 billion, a 7% increase from 2023.<\/p>\n

GAAP Loss Per Share: $(4.41), compared to earnings of $3.86 in 2023.<\/p>\n

Non-GAAP EPS: $1.15, a significant decrease from $7.51 in 2023.<\/p>\n

Growth Portfolio Revenues: $22.6 billion, a 17% increase, indicating robust performance of newer products.<\/p>\n<\/blockquote>\n

Read the complete narrative.<\/a><\/p>\n

Want to understand why a company with pressured earnings still lands at a higher fair value? This narrative leans on growth products, margin rebuild, and future cash generation assumptions. Curious which earnings power and cash flow profile support that $65.00 figure, and how they compare with traditional valuation yardsticks? The full story ties these moving parts into one clear valuation call.<\/p>\n

Result: Fair Value of $65.00 (UNDERVALUED)<\/strong><\/p>\n

Have a read of the narrative in full and understand what’s behind the forecasts.<\/a><\/p>\n

However, you still need to weigh risks such as pressure on earnings and execution on the planned cost savings that support the fair value narrative.<\/p>\n

Find out about the key risks to this Bristol-Myers Squibb narrative.<\/a><\/p>\n

Another View: What The Market Multiple Is Saying <\/p>\n

The user narrative leans on fair value of $65.00, yet the current P\/E of 16.7x sits above the US Pharmaceuticals average of 15.9x and below the peer average of 20.4x, while the fair ratio is 21x. That mix hints at both a cushion and some valuation risk. Which signal do you trust more right now?<\/p>\n

See what the numbers say about this price \u2014 find out in our valuation breakdown.<\/a><\/p>\n

\"NYSE:BMY<\/a> NYSE:BMY P\/E Ratio as at Apr 2026 Next Steps <\/p>\n

With mixed signals on valuation and sentiment throughout this article, it makes sense to review the underlying data yourself and decide quickly where you stand. You can start with the 3 key rewards and 3 important warning signs<\/a>.<\/p>\n

Looking for more investment ideas? <\/p>\n

If you stop here, you risk missing out on other opportunities that might suit your style better, so keep pushing your research a little further.<\/p>\n

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.<\/strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.<\/p>\n

Companies discussed in this article include BMY<\/a>.<\/p>\n

Have feedback on this article? Concerned about the content? Get in touch<\/a> with us directly.<\/strong> Alternatively, email editorial-team@simplywallst.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors…\n","protected":false},"author":2,"featured_media":685907,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[8818],"tags":[381,23890,748,393,24090,4884,223026,158828,16,15],"class_list":["post-927662","post","type-post","status-publish","format-standard","has-post-thumbnail","category-bristol","tag-bristol","tag-bristol-myers-squibb","tag-britain","tag-england","tag-fair-value","tag-great-britain","tag-intrinsic-value","tag-total-shareholder-return","tag-uk","tag-united-kingdom"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/116491408264733814","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/927662","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=927662"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/927662\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/685907"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=927662"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=927662"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=927662"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}